Contract awarded for products that bring improvement to health care industry

(Southlake, TX) –Reapplix announced its 3C Patch® Wound Management System has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven healthcare performance improvement company. The contract was awarded based on the recommendation of 3C Patch by hospital experts who serve on one of Vizient’s member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the healthcare industry.

Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program. Vizient member-led councils identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety or improve business operations of health care organizations.

The patented 3CPatch® System is an innovative, evidence-based biological wound therapy made entirely from the patient’s own blood – nothing else.  It is only three-layer leukocyte fibrin-rich patch backed by extensive clinical research, including a large (n=269), randomized controlled trial published in The Lancet, 2018, showing that product significantly increases the chance of healing. Effective April 13, 2021, Medicare published a National Coverage Determination for the 3C Patch for the treatment of chronic nonhealing diabetic wounds for 20 weeks.

“We are proud of this Vizient Innovative Technology contract and what it means for clinicians and their patients with chronic wounds.  We believe that empowering the patient to take an active role in their wound care can have a significant impact on the treatment outcome,” said Kira Rupprecht, CEO of Reapplix.  “With 3C Patch, the patients are literally part of their wound healing process, and this creates an incredible opportunity for engagement between the patient and the clinician as they work together to heal the wound.”

“A product receives this type of contract when it demonstrates a unique quality that differentiates it from other products on the market,” said Kelly Flaharty, senior director of contract services for Vizient. “Our member council determined that Reapplix’s 3C Patch met this standard and recognizes its potential to improve quality outcomes.”

Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents more than $130 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to health care. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.

Reapplix has established that one of the keys to successful wound treatment lies in the body’s capacity to heal – and each patient is central to that process. Founded in 2008 and headquartered in Denmark, with sales and distribution teams in the US and Europe, Reapplix won the 2018 EY Entrepreneur of the Year Award in the life science category. Every wound is personal.

For more information about the 3C Patch please visit


Kira Rupprecht, Chief Executive Officer
+1 (949) 294-0806


Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. The patented 3CPatch® System is an innovative, evidence-based biological wound therapy made entirely from the patient’s own blood – nothing else. Headquartered in Denmark, with a dedicated sales and distribution team in the US, Reapplix is poised for commercial execution with particular focus on the US market.

Every wound is personal.